Wall Street Zen Upgrades Establishment Labs (NASDAQ:ESTA) to “Buy”

Establishment Labs (NASDAQ:ESTA) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Several other brokerages also recently issued reports on ESTA. Mizuho raised their price target on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Canaccord Genuity Group increased their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Citigroup raised their target price on shares of Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Needham & Company LLC upped their price target on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Establishment Labs currently has an average rating of “Moderate Buy” and an average target price of $87.00.

Establishment Labs Stock Down 1.4%

Establishment Labs stock opened at $70.38 on Friday. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.10. The company’s 50-day moving average is $70.89 and its 200-day moving average is $59.52. The firm has a market capitalization of $2.06 billion, a PE ratio of -40.45 and a beta of 0.91. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $83.31.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The business had revenue of $64.62 million during the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.Establishment Labs’s quarterly revenue was up 45.2% on a year-over-year basis. During the same quarter last year, the company posted ($1.19) earnings per share. Sell-side analysts anticipate that Establishment Labs will post -2.41 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ESTA. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Establishment Labs by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock valued at $2,335,000 after buying an additional 9,557 shares in the last quarter. Tyro Capital Management LLC increased its stake in Establishment Labs by 0.3% during the 2nd quarter. Tyro Capital Management LLC now owns 1,066,721 shares of the company’s stock worth $45,560,000 after acquiring an additional 2,835 shares during the period. Geode Capital Management LLC raised its holdings in Establishment Labs by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after acquiring an additional 299 shares in the last quarter. Garnet Equity Capital Holdings Inc. acquired a new position in Establishment Labs in the 2nd quarter valued at $7,062,000. Finally, SG Americas Securities LLC grew its holdings in shares of Establishment Labs by 94.2% during the 2nd quarter. SG Americas Securities LLC now owns 8,712 shares of the company’s stock worth $372,000 after purchasing an additional 4,226 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.